20:01 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure, a...
04:55 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Kadmon reports Phase IIa data for chronic GvDH candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported data from the Phase IIa KD025-208 trial evaluating KD025 to treat steroid-dependent or steroid-refractory chronic graft-versus-host disease (GvHD) in patients who have received an allogeneic bone marrow transplant (BMT) or...
01:22 , Jan 4, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models An allogeneic macaque model of HSCT-associated GvHD could be used to screen for therapies. Transplant of HSCs between pairs of allogeneic cynomolgus macaques that harbored matching major histocompatibility complex (MHC) alleles at all...
22:05 , Jul 25, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; drug properties

TECHNOLOGY: Cellular assays; high throughput screening; toxicology A high throughput yeast- and DNA barcode-based platform could be used to screen for changes in protein-protein interactions induced by drug compounds. The platform involves first generating libraries of...
19:11 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Aurinia starts Phase III AURORA trial of voclosporin for lupus nephritis

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) began the Phase III AURORA trial evaluating Luveniq voclosporin (LX211) to treat lupus nephritis. The double-blind, international trial will enroll about 320 patients to receive twice-daily 23.7 mg voclosporin plus...
15:46 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

Voclosporin regulatory update

Aurinia said it believes results from the planned Phase III AURORA trial and the completed Phase IIb AURA-LV trial of voclosporin will be sufficient for regulatory submissions of the product in the EU and Japan...
23:42 , Apr 7, 2017 |  BC Extra  |  Company News

Aurinia rises as regulators clarify path for voclosporin

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) said it believes results from a planned Phase III study and a completed Phase IIb study of voclosporin (LX211) will be sufficient for regulatory submissions in the EU and Japan....
00:51 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies suggest topical tacrolimus could help treat lymphedema. In a mouse tail model of lymphedema, a topical formulation of tacrolimus decreased tail swelling and volume, soft tissue thickness, infiltration of inflammatory cells in...
22:47 , Mar 14, 2017 |  BC Extra  |  Financial News

Aurinia slips after taking haircut in $150.5M follow-on

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) raised $150.5 million through the sale of 22.3 million shares at $6.75 in a follow-on underwritten by Leerink and Cantor Fitzgerald. The price is a 36% discount to the company's...
20:09 , Mar 10, 2017 |  BC Week In Review  |  Clinical News

Voclosporin: Additional Ph IIb AURA-LV data

Additional data from the double-blind, international Phase IIb AURA-LV trial in 265 patients with active lupus nephritis showed that twice-daily 23.7 and 39.5 mg oral voclosporin plus standard of care (SOC) mycophenolate mofetil (MMF) and...